RxDoctor Payments Data

Scott Harder, DO

Family Medicine · Augusta, KSNPI 1932166154

Payments from drug & device makers

$5,192in general payments, 2019–2025

Across 336 payments — averaging $15.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$857
  • Novo Nordisk$652
  • AstraZeneca$498
  • Astellas Pharma US Inc$479
  • Lilly USA, LLC$426
  • Bayer$406
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,172100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,192 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Kansas.

See all family medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$162,275
Medicare patients
435
Services billed
3,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$81,334
OzempicSemaglutide64$58,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$47,449
JardianceEmpagliflozin69$43,639
XifaxanRifaximin16$33,395
Tresiba Flextouch U-100Insulin Degludec65$18,452
MounjaroTirzepatide13$14,358
JanuviaSitagliptin Phosphate18$13,422
XareltoRivaroxaban39$11,431
TradjentaLinagliptin25$11,072
MyrbetriqMirabegron43$10,727
LinzessLinaclotide14$8,104
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$7,660
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc68$6,923
BrilintaTicagrelor27$6,304

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$163$81,334189 claims
Novo NordiskOzempic$652$58,74364 claims
Boehringer IngelheimJardiance, Tradjenta$34$54,71194 claims
GSKTrelegy Ellipta, Anoro Ellipta$49$53,22078 claims
Lilly USA, LLCMounjaro$426$14,35813 claims
MerckJanuvia$63$13,42218 claims
AstraZenecaBrilinta, Symbicort$498$12,33153 claims
AbbVieLinzess, Synthroid$857$11,48162 claims
Johnson & JohnsonXarelto$50$11,43139 claims
Astellas Pharma US IncMyrbetriq$479$10,72743 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Kansas.

Other family medicine in Augusta

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →